Alfentanil sublingual - Orexo

Drug Profile

Alfentanil sublingual - Orexo

Alternative Names: OX-51

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator Orexo
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acute pain

Highest Development Phases

  • Phase II/III Acute pain

Most Recent Events

  • 29 Oct 2015 Alfentanil sublingual - Orexo is available for licensing worldwide as of 29 Oct 2015. http://www.orexo.com/en/
  • 31 Jul 2015 Alfentanil sublingual is still in phase-II/III development for Acute Pain (prevention) in Europe
  • 28 Aug 2013 Efficacy & adverse events data from a phase II/III trial in Acute pain (prevention) released by Orexo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top